Juno Therapeutics, Inc. Report issue

Contributed to NME For profit Phase 1 Phase 2
Founded: Seattle WA United States (2013)
Status: Acquired by Celgene (2018) → now Bristol-Myers Squibb (2019)

Organization Overview

First Clinical Trial
2015
NCT02498912
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Early Clinical Development | Juno | Juno Therapeutics, a Subsidiary of Celgene | Juno Therapeutics, Inc. | JunoTherapeutics, Inc.

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Disease (Phase 2)

Immune System Diseases (Phase 2)

Immunoproliferative Disorders (Phase 2)

Leukemia (Phase 2)

Leukemia, Lymphocytic, Chronic, B-Cell (Phase 2)

Leukemia, Lymphoid (Phase 2)

Lymphatic Diseases (Phase 2)

Lymphoma (Phase 2)

Lymphoma, B-Cell (Phase 2)

Lymphoma, Follicular (Phase 2)

Lymphoma, Large B-Cell, Diffuse (Phase 2)

Lymphoma, Mantle-Cell (Phase 1)

Lymphoma, Non-Hodgkin (Phase 2)

Lymphoproliferative Disorders (Phase 2)

Multiple Myeloma (Phase 2)

Neoplasms (Phase 2)

Neoplasms by Histologic Type (Phase 2)

Neoplasms, Plasma Cell (Phase 2)

Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 18
  • # of Trial APIs: 19